News

MEDISEARCHER NEWS Australia · Medication safety & unapproved peptides · 6 November 2026 In brief Australia’s Therapeutic Goods Administration (TGA) issued a safety advisory on 5 November 2026 after testing unapproved Synedica peptide products. Three tested product types labelled as containing TB-500 had no detectable TB-500. Tested Synedica Retatrutide 10 mg products contained less retatrutide … Read more

MEDISEARCHER NEWS Australia · Weight-loss medication & prescription access · 5 November 2026 In brief Australia’s Therapeutic Goods Administration (TGA) registered Wegovy weight-loss tablets on 3 November 2026. This is Australia’s first oral GLP-1 medicine approved specifically for weight management. Four tablet strengths have been registered: 1.5 mg, 4 mg, 9 mg and 25 mg. … Read more

MEDISEARCHER NEWS United States · HPV & immunotherapy · 1 November 2026 In brief The US Food and Drug Administration has granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis (RRP), a rare chronic airway disease caused by HPV. Voceryq is the first plasmid DNA-based immunotherapy approved in the United States. RRP causes … Read more

MEDISEARCHER NEWS United Kingdom · Gene editing & inherited blood disorders · 31 October 2026 In brief The UK has expanded the authorisation of Casgevy, allowing eligible children from age five with severe sickle cell disease or transfusion-dependent beta thalassaemia to receive the CRISPR gene-editing treatment. Casgevy was previously authorised in the UK only for … Read more

MEDISEARCHER NEWS United Kingdom · Drug safety · 31 October 2026 In brief The UK medicines regulator is introducing stronger safety information for antidepressants following a major review involving patients, families and independent experts. Patient information leaflets will receive a new boxed warning highlighting the risk of suicidal thoughts and behaviours. For certain antidepressants, leaflets … Read more

MEDISEARCHER NEWS Global · Diabetes & weight management · 29 October 2026 In brief Experimental drug retatrutide has beaten Ozempic 2 mg in a head-to-head Phase III trial involving 1,298 adults with type 2 diabetes. At 80 weeks, participants receiving retatrutide lost an average of 19.5% to 20.9% of their body weight, compared with 9.4% … Read more

MEDISEARCHER NEWS Poland · Medicine access & reimbursement · 29 October 2026 In brief Poland’s Council of Ministers approved a major draft reform of the medicine reimbursement system on 27 October 2026. The package contains almost 200 proposed changes covering medicine prices, reimbursement procedures, drug shortages, imported medicines and access to new therapies. Patients choosing … Read more

MEDISEARCHER NEWS European Union · Breast cancer · 28 October 2026 The European Commission has approved Enhertu (trastuzumab deruxtecan) for certain adults with HER2-positive early breast cancer, moving the medicine into a curative-intent setting where treatment is designed to prevent the cancer from returning after surgery. The new indication applies to adults with resected HER2-positive … Read more

MEDISEARCHER NEWS United Kingdom · Psoriasis · 26 October 2026 The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Icotyde (icotrokinra hydrochloride), a once-daily tablet for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic treatment. The approval is particularly notable because icotrokinra selectively blocks the interleukin-23 (IL-23) receptor. Injectable … Read more

MEDISEARCHER NEWS United States · Rectal cancer · 24 October 2026 The US Food and Drug Administration has approved Jemperli (dostarlimab-gxly) for certain adults with locally advanced rectal cancer, creating a treatment pathway that may allow some eligible patients to avoid chemotherapy, radiation and major rectal surgery. The accelerated approval, announced on 19 October 2026, … Read more